Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
25.06. | Toleranzia AB: Toleranzia applies for delisting of the Company's shares from Nasdaq First North Growth Market, conditional upon completion of the merger with Flerie | 41 | GlobeNewswire (Europe) | Toleranzia AB (publ) ("Toleranzia" or the "Company") has today, in connection with the upcoming merger between Toleranzia and Flerie (the "Merger"), which was announced through a press release on 25... ► Artikel lesen | |
13.06. | Nanologica AB: Statement From The Board Of Directors Of Nanologica AB (publ) Regarding The Mandatory Bid From Flerie Invest Ab | 256 | GlobeNewswire (Europe) | The Board of Directors of Nanologica AB (publ) ("Nanologica" or the "Company") unanimously recommends the shareholders of Nanologica not to accept the mandatory cash offer made by Flerie Invest AB ("Flerie")... ► Artikel lesen | |
12.06. | Flerie AB: Flerie's portfolio company Nanologica has received its first U.S. order | 430 | GlobeNewswire (Europe) | Stockholm, Sweden, June 12, 2025. Flerie AB's (publ) portfolio company Nanologica has announced that the company has secured an order for its silica-based purification media, NLAB Saga®, from a new... ► Artikel lesen | |
FLERIE Aktie jetzt für 0€ handeln | |||||
03.06. | Flerie AB: Flerie's portfolio company KAHR Bio presents positive results from its Phase II trial with DSP107 in combination with anti-PD-L1 in colorectal cancer | 64 | GlobeNewswire (Europe) | Stockholm, Sweden, June 3, 2025. Flerie AB's (publ) portfolio company KAHR Bio has communicated that they have presented positive Phase II results at the 2025 ASCO Annual Meeting.
The results indicate... ► Artikel lesen | |
23.05. | Nanologica AB: Comment from the Board of Nanologica AB (publ) Regarding the Mandatory Bid from Flerie Invest AB | 584 | GlobeNewswire (Europe) | Nanologica AB's (publ) ("Nanologica") main owner Flerie Invest AB ("Flerie") has today, May 23, 2025, made a mandatory cash offer of SEK 1.00 per share to the shareholders of Nanologica (the "Offer").... ► Artikel lesen | |
23.05. | Flerie AB: Flerie Invest AB announces a mandatory cash offer to the shareholders of Nanologica AB (publ) | 585 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT, DIRECTLY OR INDIRECTLY, BE DISTRIBUTED OR PUBLISHED IN OR INTO ANY JURISDICTION (INCLUDING WITHOUT LIMITATION AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE... ► Artikel lesen | |
14.05. | Flerie AB: The General Meetings of Flerie and Toleranzia respectively have approved the merger plan and the General Meeting in Flerie has resolved on issuance of the merger consideration | 74 | GlobeNewswire (Europe) | THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEELAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD... ► Artikel lesen | |
30.04. | Flerie AB: Flerie receives FDI-approval for the merger with Toleranzia | 198 | GlobeNewswire (Europe) | THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEELAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD... ► Artikel lesen | |
26.04. | Nanologica AB: Nanologica AB Informs that Flerie Invest AB has Passed the Threshold for Mandatory Bid | 547 | GlobeNewswire (Europe) | Nanologica's main owner Flerie Invest AB ("Flerie") has acquired additional shares in Nanologica AB with the result that a mandatory bid obligation has arisen. Flerie's total holding in Nanologica after... ► Artikel lesen | |
22.04. | LIPUM AB: Lipum looks ahead to phase II with backing from Flerie | 3 | Cision News | ||
16.04. | Flerie AB: Flerie AB Interim Report January - March 2025 | 103 | GlobeNewswire (Europe) | The period in briefNet asset value was SEK 3,947 million (3,416) and net asset value per share was SEK 50.56 (56.24), adjusted net asset value per share was 51.88 (56.24). Change in net asset value... ► Artikel lesen | |
14.04. | Flerie AB: Flerie's portfolio company Lipum presents positive results from its Phase I trial with SOL-116 | 141 | GlobeNewswire (Europe) | Stockholm, Sweden, April 14, 2025. Flerie AB announces that its portfolio company Lipum has presented final results from a Phase I trial evaluating SOL-116 in healthy volunteers and patients with rheumatoid... ► Artikel lesen | |
25.03. | Toleranzia AB: Statement by the Board of Directors of Toleranzia in view of the merger offer by Flerie | 136 | GlobeNewswire (Europe) | The Board of Directors of Toleranzia AB (publ) ("Toleranzia") unanimously recommends the shareholders of Toleranzia to vote in favour of the completion of the merger between Toleranzia and Flerie AB... ► Artikel lesen | |
25.03. | Toleranzia AB: Flerie and Toleranzia have agreed on a merger plan to take Toleranzia private | 140 | GlobeNewswire (Europe) | THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEELAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD... ► Artikel lesen | |
24.03. | Nanologica AB: Nanologica AB Extends Existing Loan from Flerie | 871 | GlobeNewswire (Europe) | Nanologica has extended the existing loan from Flerie Invest AB. The end date for the loan has been extended to July 2, 2027 from previous July 5, 2025.
The loan will be paid off in stages according... ► Artikel lesen | |
22.01. | Flerie AB: Year-end report 2024 | 184 | GlobeNewswire (Europe) | October - December 2024Net asset value was SEK 4,198 million (3,566) and net asset value per share was SEK 53.77 (58.71), adjusted net asset value per share was 55.09 (58.71)Change in net asset value... ► Artikel lesen | |
16.10.24 | Flerie AB: Interim report January - September 2024 | 220 | GlobeNewswire (Europe) | July - September 2024Net asset value was SEK 4,262 million (3,212) and net asset value per share was SEK 54.59 (52.88), adjusted net asset value per share was SEK 55.91 (52.88)Change in net asset value... ► Artikel lesen | |
24.07.24 | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 24.07.2024 | 591 | Xetra Newsboard | The following instruments on XETRA do have their first trading 24.07.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 24.07.2024
Aktien
1 US0352431045 Anhui Conch Cement Co.... ► Artikel lesen | |
23.07.24 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 23.07.2024 | 3.571 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 23.07.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 23.07.2024ISIN NameAU000000AWC3 ALUMINA... ► Artikel lesen | |
23.07.24 | XFRA ISIN CHANGE | 747 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenUS51817R1068 LATAM Airlines Group S.A. 23.07.2024 US51817R2058 LATAM Airlines Group S.A. 24.07.2024 Tausch 2000:1SE0022421467 Flerie... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
HAEMATO | 11,200 | -0,88 % | M1 Kliniken: Verkauf von HAEMATO PHARM im Fokus | Die M1 Kliniken AG steht vor dem möglichen Verkauf eines Teils der Konzern-Aktivitäten: Die zur Gruppe gehörende HAEMATO AG prüft derzeit ein verbindliches Angebot für den Verkauf ihrer Tochtergesellschaft... ► Artikel lesen | |
EYEPOINT PHARMACEUTICALS | 7,888 | -3,59 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
PHOTOCURE | 4,560 | +1,22 % | Photocure ASA: Results for the first quarter of 2025 | OSLO, Norway, May 8, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 125.3 million in the first quarter of 2025 (Q1 2024: NOK 116.8 million)... ► Artikel lesen | |
BAYER | 26,745 | +1,48 % | EQS-PVR: Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Bayer Aktiengesellschaft
Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
26.06.2025... ► Artikel lesen | |
EYENOVIA | 15,840 | 0,00 % | Eyenovia, Inc.: Eyenovia Announces Rebranding and Corporate Name Change to Hyperion DeFi, Inc. | Name change reflects company's leadership position with its cryptocurrency treasury reserve strategy focused on the HYPE token Company to commence trading on Nasdaq under the symbol "HYPD" effective... ► Artikel lesen | |
MERCK KGAA | 112,80 | +0,09 % | DAX-Check LIVE: Aroundtown, Infineon, Mercedes-Benz, Merck, Munich Re, SUSS, TUI, Zalando im Fokus | Der DAX hat nach seiner jüngsten Erholung die Verluste vom Wochenbeginn ausgeweitet und den Handel auf dem Tagestief beendet. Der Leitindex büßte ein Prozent ein und schloss bei 23.673 Punkten. Experten... ► Artikel lesen | |
NOVO NORDISK | 59,51 | +0,46 % | Novo Nordisk geht neue Wege: Fokus auf digitale Abnehmmärkte | Die Aktie von Novo Nordisk steht aktuell bei 57,62?EUR und zeigt sich trotz jüngster Turbulenzen stabil. Der dänische Pharmakonzern setzt nun auf eine überraschende Allianz: Gemeinsam mit WeightWatchers... ► Artikel lesen | |
SANOFI | 83,60 | -0,18 % | Minimale Kursveränderung bei Sanofi SA-Aktie (82,73 €) | Wenig Kursbewegung zur Stunde bei dem Anteilsschein von Sanofi SA . Das Wertpapier notiert aktuell bei 82,73 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei dem Anteilsschein von... ► Artikel lesen | |
PFIZER | 21,460 | 0,00 % | Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen | ||
METSERA | 28,860 | 0,00 % | Metsera, Inc.: Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i | Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated... ► Artikel lesen | |
HARROW | 30,580 | 0,00 % | Formosa Pharmaceuticals Inc.: Harrow Health, Inc. Acquires U.S. Commercial Rights to BYQLOVI (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals | TAIPEI, June 9, 2025 /PRNewswire/ -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan -based Formosa Pharmaceuticals... ► Artikel lesen | |
AQUESTIVE THERAPEUTICS | 3,655 | +7,50 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | Submitted NDA for Anaphylm (epinephrine), the first and only oral sublingual film for patients with severe allergic reactions Advancing commercial readiness efforts with a planned Q1 2026 launch of... ► Artikel lesen | |
ASTRAZENECA | 121,25 | +0,46 % | BERNSTEIN RESEARCH stuft ASTRAZENECA auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat die Einstufung für Astrazeneca mit einem Kursziel von 16500 Pence auf "Outperform" belassen. Justin Smith zeigt sich in einer... ► Artikel lesen | |
VYNE THERAPEUTICS | 1,510 | 0,00 % | VYNE Therapeutics Inc.: VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202 | ||
VERONA PHARMA PLC ADR | 76,20 | -0,26 % | Verona Pharma: Über 510 Prozent in einem Jahr - Rally ohne Ende | Die unfassbare Rally bei der Aktie von Verona Pharma geht in die nächste Runde. Am Mittwoch konnte der Titel an der Nasdaq 92,98 Dollar eine neue Bestmarke markieren, wodurch das Papier auf Sicht von... ► Artikel lesen |